Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for treatment-refractory acquired aplastic anemia in children
IRCT20221129056655N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of romiplostim in acquired aplastic anemia (AAA), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Complete hematologic response or partial hematologic response at week 27. Started Jun 2023; status: completed.
02
Drugs
romiplostim
03
Conditions
acquired aplastic anemia (AAA)
Beyond the preview
Go deeper on IRCT20221129056655N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221129056655N1.